Premium
Expression of CD304/neuropilin‐1 in adult b‐cell lymphoblastic leukemia/lymphoma and its utility for the measurable residual disease assessment
Author(s) -
Chatterjee Gaurav,
Dudakia Vishesh,
Ghogale Sitaram,
Deshpande Nilesh,
Girase Karishma,
Chaturvedi Anumeha,
Shetty Dhanlaxmi,
Senger Manju,
Jain Hasmukh,
Bagal Bhausaheb,
Bonda Avinash,
Punatar Sachin,
Gokarn Anant,
Khattry Navin,
Patkar Nikhil V.,
Gujral Sumeet,
Subramanian Papagudi G.,
Tembhare Prashant R.
Publication year - 2021
Publication title -
international journal of laboratory hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.705
H-Index - 55
eISSN - 1751-553X
pISSN - 1751-5521
DOI - 10.1111/ijlh.13456
Subject(s) - minimal residual disease , medicine , flow cytometry , neuropilin 1 , lymphoma , bone marrow , oncology , leukemia , b cell , immunophenotyping , cd34 , immunology , cancer research , antibody , biology , stem cell , vegf receptors , vascular endothelial growth factor , genetics
Many new markers are being evaluated to increase the sensitivity and applicability of multicolor flow cytometry (MFC)‐based measurable residual disease (MRD) monitoring. However, most of the studies are limited to childhood B‐cell lymphoblastic leukemia/lymphoma (B‐ALL), and reports in adult B‐ALL are extremely scarce and limited to small cohorts. We studied the expression of CD304/neuropilin‐1 in a large cohort of adult B‐ALL patients and evaluated its practical utility in MFC‐based MRD analysis. Methods CD304 was studied in blasts from adult B‐ALL patients and normal precursor B cells (NPBC) from non‐B‐ALL bone marrow samples using MFC. CD304 expression intensity and pattern were studied with normalized‐mean fluorescent intensity (nMFI) and coefficient of variation of immunofluorescence (CVIF), respectively. MFC‐based MRD was performed at end of induction (EOI; day‐35), end of consolidation (EOC; day 78‐80), and subsequent follow‐up (SFU) time points. Results CD304 was positive in 120/214(56.07%) and was significantly associated with BCR‐ABL1 fusion ( P = .001). EOI‐MRD and EOC‐MRD were positive in 129/214(60.3%) and 50/81(61.72%), respectively. CD304 was positive in a significant percentage of EOI (48%, 62/129) and EOC (52%, 26/50) MRD‐positive B‐ALL samples. Its expression was retained, lost, and gained in 73.7%, 26.3%, and 11.3% of EOI‐MRD and 85.7%, 14.3%, and none of EOC‐MRD samples, respectively. Low‐level MRD (<0.01%) was detectable in 34 of all (EOI + EOC + SFU = 189) MRD‐positive samples, and CD304 was found useful in 50% of these samples. Conclusion CD304 is commonly expressed in adult B‐ALL and clearly distinguish B‐ALL blasts from normal precursor B cells. It is a stable MRD marker and distinctly useful in the detection of MFC‐based MRD monitoring, especially in high‐sensitivity MRD assay.